Clinical Trial Update: LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating LILRB4 STAR-T Cells for relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• LILRB4 STAR-T Cells

Snippet

Sponsor: Peking University People's Hospital | Conditions: Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia | Phase 1 | Status: COMPLETED